TheStreet's Jim Cramer says many people felt Mannkind's inhaled insulin drug Afrezza would fail and as a result, 28-percent of the float was short and any good news would get the stock going. On the other hand, those who believe in the drug say this is the beginning of a major move for the stock since Mannkind has already spent a "fortune" developing Afrezza. However, Cramer says he is completely neutral and sometimes it's better to admit you don't know where something is going.

At the time of publication, Cramer was long ___.

If you liked this article you might like

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind Stock Drops Following Changes to Its Insulin Product

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Insulin Drug Offers Hope for MannKind